Assessment of Pharmacokinetic Effects of Herbal Medicines on Escitalopram

References

• Marvel CL, Paradiso S. Cognitive and neurological impairment in mood disorders. Psychiatr Clin North Am. 2004;27(1):19–viii. doi:10.1016/S0193-953X(03)00106-0
   PubMed Web of Science ®Google Scholar
• Knight MJ, Baune BT. Cognitive dysfunction in major depressive disorder. Curr Opin Psychiatry. 2018;31:26–31. doi:10.1097/YCO.0000000000000378
   PubMed Web of Science ®Google Scholar
• Bains N, Abdijadid S. Major Depressive Disorder. Treasure Island (FL): StatPearls; 2023.
   Google Scholar
• Mathers CD, Loncar D, Samet J. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:e442. doi:10.1371/journal.pmed.0030442
   PubMed Web of Science ®Google Scholar
• Edinoff AN, Akuly HA, Hanna TA, et al. Selective serotonin reuptake inhibitors and adverse effects: a narrative review. Neurol Int. 2021;13(3):387–401. doi:10.3390/neurolint13030038
   PubMed Web of Science ®Google Scholar
• Bakshi A, Tadi P. Biochemistry, Serotonin. Treasure Island (FL): StatPearls; 2023.
   Google Scholar
• Rao N. The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet. 2007;46:281–290. doi:10.2165/00003088-200746040-00002
   PubMed Web of Science ®Google Scholar
• von Moltke LL, Greenblatt DJ, Giancarlo GM, Granda BW, Harmatz JS, Shader RI. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos. 2001;29:1102–1109.
   PubMed Web of Science ®Google Scholar
• Noehr-Jensen L, Zwisler ST, Larsen F, Sindrup SH, Damkier P, Brosen K. Escitalopram is a weak inhibitor of the CYP2D6-catalyzed O-demethylation of (+)-tramadol but does not reduce the hypoalgesic effect in experimental pain. Clin Pharmacol Ther. 2009;86:626–633. doi:10.1038/clpt.2009.154
   PubMed Web of Science ®Google Scholar
• Noehr-Jensen L, Zwisler ST, Larsen F, et al. Impact of CYP2C19 phenotypes on escitalopram metabolism and an evaluation of pupillometry as a serotonergic biomarker. Eur J Clin Pharmacol. 2009;65(9):887–894. doi:10.1007/s00228-009-0657-0
   PubMed Web of Science ®Google Scholar
• Sung S-H, Han J-E, Ryu J-Y, et al. Current status and future perspective of external herbal dispensaries preparing traditional herbal medicine in South Korea: the first national-wide survey results. BMC Complement Med Ther. 2020;20(1):354. doi:10.1186/s12906-020-03094-0
   PubMedGoogle Scholar
• Na DH, Ji HY, Park EJ, Kim MS, Liu KH, Lee HS. Evaluation of metabolism-mediated herb-drug interactions. Arch Pharm Res. 2011;34:1829–1842. doi:10.1007/s12272-011-1105-0
   PubMed Web of Science ®Google Scholar
• Fugh-Berman A, Ernst E. Herb-drug interactions: review and assessment of report reliability. Br J Clin Pharmacol. 2001;52:587–595. doi:10.1046/j.0306-5251.2001.01469.x
   PubMed Web of Science ®Google Scholar
• Rombola L, Scuteri D, Marilisa S, et al. Pharmacokinetic interactions between herbal medicines and drugs: their mechanisms and clinical relevance. Life Basel. 2020;10:1.
   Web of Science ®Google Scholar
• Hussain MS. Patient counseling about herbal-drug interactions. Afr J Tradit Complem. 2011;8:152–163.
   PubMedGoogle Scholar
• Singh A, Zhao K. Herb-drug interactions of commonly used Chinese medicinal herbs. Int Rev Neurobiol. 2017;135:197–232.
   PubMed Web of Science ®Google Scholar
• Peng SQ, Zhou YL, Lu M, Wang QZ. Review of herbal medicines for the treatment of depression. Nat Prod Commun. 2022;17:1.
   Web of Science ®Google Scholar
• Canbolat F, Tasdemir Erinc DM, Evrensel A, Aydin A, Tarhan KN. Quantitation of escitalopram and its metabolites by liquid chromatography-tandem mass spectrometry in psychiatric patients: new metabolic ratio establishment. Basic Clin Pharmacol Toxicol. 2019;124(3):285–297. doi:10.1111/bcpt.13133
   PubMed Web of Science ®Google Scholar
• Hicks JK, Bishop JR, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 2015;98(2):127–134. doi:10.1002/cpt.147
   PubMed Web of Science ®Google Scholar
• Heatherington AC, Vicini P, Golde H. A pharmacokinetic/pharmacodynamic comparison of SAAM II and PC/WinNonlin modeling software. J Pharm Sci. 1998;87(10):1255–1263. doi:10.1021/js9603562
   PubMed Web of Science ®Google Scholar
• Lin CC, Arkenau HT, Lu SR, et al. A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas. Br J Cancer. 2019;121:131–138. doi:10.1038/s41416-019-0503-9
   PubMed Web of Science ®Google Scholar
• Sang-Jun P, In-Sun O, Minjung P, Bo-Hyoung J, Ju-Young S. Concurrent use of prescribed OTC · ETC drugs and herbal medicines in South Korea: exploring potential herb-drug interactions. Yakhak Hoeji. 2022;66:90–96. doi:10.17480/psk.2022.66.2.90
   Google Scholar
• Agbabiaka TB, Spencer NH, Khanom S, Goodman C. Prevalence of drug-herb and drug-supplement interactions in older adults: a cross-sectional survey. Br J Gen Pract. 2018;68:e711–e717. doi:10.3399/bjgp18X699101
   PubMed Web of Science ®Google Scholar
• Go H, Ryuk JA, Hwang JT, Ko BS. Effects of three different formulae of Gamisoyosan on lipid accumulation induced by oleic acid in HepG2 cells. Integr Med Res. 2017;6:395–403. doi:10.1016/j.imr.2017.08.004
   PubMed Web of Science ®Google Scholar
• Jung MY, Seo CS, Baek SE, et al. Analysis and identification of active compounds from gami-soyosan toxic to MCF-7 human breast adenocarcinoma cells. Biomolecules. 2019;9. doi:10.3390/biom9070272
   Web of Science ®Google Scholar
• Gan Y, Liu H, Yang L, Yang K. Effect of banxiaxiexin tang on treatment of functional dyspepsia: a meta-analysis of randomized controlled trials. J Tradit Chin Med. 2014;34:140–144. doi:10.1016/S0254-6272(14)60067-4
   PubMed Web of Science ®Google Scholar
• Shin MR, Seo BI, Son CG, Roh SS, An HJ. Banhasasim-tang treatment reduces the severity of esophageal mucosal ulcer on chronic acid reflux esophagitis in rats. Biomed Res Int. 2017;2017:7157212. doi:10.1155/2017/7157212
   PubMed Web of Science ®Google Scholar
• Lyu YR, Kim KI, Yang C, et al. Efficacy and safety of ojeok-san plus saengmaek-san for gastroesophageal reflux-induced chronic cough: a pilot, randomized, double-blind, placebo-controlled trial. Front Pharmacol. 2022;13:787860. doi:10.3389/fphar.2022.787860
   PubMedGoogle Scholar
• Patton EA, Cunningham P, Noneman M, et al. Acute administration of ojeok-san ameliorates pain-like behaviors in pre-clinical models of inflammatory bowel diseases. Nutrients. 2023:15. doi:10.3390/nu16010015
   PubMed Web of Science ®Google Scholar
• Park S, Yang EJ. Anti-inflammatory effect of gamisoyo-san in an animal model of amyotrophic lateral sclerosis. Evid Based Complement Alternat Med. 2018;2018:8580152. doi:10.1155/2018/8580152
   PubMed Web of Science ®Google Scholar
• Kim H-M, Liu K-H. Screening for inhibitory effect on nine CYP isoforms by 20 herbal medications. J Life Sci. 2007;17:334–339. doi:10.5352/JLS.2007.17.3.334
   Google Scholar
• Jin SE, Seo CS, Shin HK, Ha H. Traditional herbal formulas to as treatments for musculoskeletal disorders: their inhibitory effects on the activities of human microsomal cytochrome p450s and udp-glucuronosyltransferases. Pharmacogn Mag. 2016;12(48):241–252. doi:10.4103/0973-1296.192205
   PubMed Web of Science ®Google Scholar
• Jin SE, Ha H, Shin HK. Effects of herbal formulas bojungikgi-tang and palmijihwang-hwan on inflammation in RAW 264.7 cells and the activities of drug-metabolizing enzymes in human hepatic microsomes. J Med Food. 2018;21:1173–1187. doi:10.1089/jmf.2017.4123
   PubMed Web of Science ®Google Scholar
• Woroń J, Siwek M. Unwanted effects of psychotropic drug interactions with medicinal products and diet supplements containing plant extracts. Niepożądane efekty interakcji leków psychotropowych z produktami leczniczymi i suplementami diety zawierającymi wyciągi roślinne. Psychiatr Pol. 2018;52:983–996. Polish. doi:10.12740/PP/OnlineFirst/80998
   PubMed Web of Science ®Google Scholar
• Siwek M, Woroń J, Wrzosek A, Gupało J, Chrobak AA. Harder, better, faster, stronger? Retrospective chart review of adverse events of interactions between adaptogens and antidepressant drugs. Front Pharmacol. 2023;14:1271776. doi:10.3389/fphar.2023.1271776
   PubMed Web of Science ®Google Scholar
• Vaughn SE, Strawn JR, Poweleit EA, Sarangdhar M, Ramsey LB. The impact of marijuana on antidepressant treatment in adolescents: clinical and pharmacologic considerations. J Pers Med. 2021;11:615. doi:10.3390/jpm11070615
   PubMed Web of Science ®Google Scholar
• Bettonte S, Berton M, Stader F, Battegay M, Marzolini C. Management of drug interactions with inducers: onset and disappearance of induction on cytochrome P450 3A4 and uridine diphosphate glucuronosyltransferase 1A1 substrates. Eur J Drug Metab Pharmacokinet. 2023;48:353–362. doi:10.1007/s13318-023-00833-9
   PubMed Web of Science ®Google Scholar
• Park SI, Park JY, Park MJ, Yim SV, Kim BH. Effects of ojeok-san on the pharmacokinetics of celecoxib at steady-state in healthy volunteers. Basic Clin Pharmacol. 2018;123:51–57. doi:10.1111/bcpt.12971
   Google Scholar
• Sun S, Wang Y, Wu A, Ding Z, Liu X. Influence factors of the pharmacokinetics of herbal resourced compounds in clinical practice. Evid Based Complement Alternat Med. 2019;2019:1983780. doi:10.1155/2019/1983780
   PubMed Web of Science ®Google Scholar